In this contest, THRβ-selective thyromimetic TG68 has been found to provide beneficial effects by mimicking thyroid hormone in its ability to reduce hepatic fat accumulation in the absence of unwanted toxic effects, mainly mediated by THRα, representing an attractive candidate for the treatment of primarily lipid-related metabolic disorders, including dyslipidemia and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) [24]. Here, THRA is linked to metabolic dysfunction-associated steatotic liver disease.